Dennis Willson, JD

Mr. Willson is President & CEO of ITF Pharma, Inc. and is co-founder and chairman of Hsiri Therapeutics, LLC, a start-up company focused on the development of new antibiotics for drug-resistant infections. He was formerly the President & CEO of Cytokine PharmaSciences, Inc., a biopharmaceutical company focused on women’s health, inflammation and cancer. As one […]

Ronald Lennox, D.Phil

Dr. Lennox has been an active investor and entrepreneur in early stage life science companies for over twenty five years. He has served on the boards of over eighteen companies including General Surgical Innovations, Inc (acquired by Tyco International Corp), GeneOhm Sciences, Inc. (acquired by Becton Dickinson and Co.) and Applied Molecular Evolution, Inc. (acquired […]

Walter Ogier

Walter Ogier co-founded Harvard-affiliated Acetylon Pharmaceuticals (Boston MA, oncology and neurodegeneration) in 2008 and served as its President & CEO until its sale to Celgene in 2016. He subsequently served as founding President & CEO of Regenacy Pharmaceuticals (neuropathy and hemoglobinopathies), which was spun out of Acetylon at the time of the Celgene acquisition. In […]

David Wurzer

Mr. Wurzer is Executive Vice President and Chief Investment Officer at Connecticut Innovations Inc., a leading early stage life science investor nationwide. Prior to joining CI, Mr. Wurzer had extensive senior-level experience in operations and finance, including more than 10 years as executive vice president, treasurer and CFO of CuraGen Corporation (NASDAQ: CRGN), where he […]

Frank C. Sciavolino, PhD

Dr. Sciavolino has extensive experience in the pharmaceutical industry, including a distinguished 35 year career at Pfizer Global R&D. At Pfizer, Dr. Sciavolino held various management roles and responsibilities in drug discovery, development, registration and licensing, culminating in a role as Vice President of R&D Operations, in which he oversaw a team of 1,000 scientists […]